Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 979
countries
28
conditions
2 106

38 trials match your criteria

Chronic lymphocytic leukaemia+2

Not yet recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Infection prophylaxis

Not yet recruiting

Study of human normal immunoglobulin to prevent major infections in patients with hypogammaglobulinemia and autoimmune/rheumatic disease on B‑cell depletion therapy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

COVID-19

Not yet recruiting

Study of Intravenous Immunoglobulin Added to Standard Treatment for COVID-19 in Patients with Severely Weakened Immune System Due to B-cell Problems

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Small fibre neuropathy

Not yet recruiting

Study on the Effect of Human Normal Immunoglobulin and Sodium Chloride on Pain Relief in Patients with Idiopathic Painful Sensory Neuropathy

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Sodium Chloride

Primary immunodeficiency syndrome

Not recruiting

Study on the Effects of TAK-881 and Hyaluronidase in Adults with Primary Immunodeficiency Diseases

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Primary immunodeficiency syndrome

Not recruiting

Study on Long-term Safety of TAK-881 (Human Normal Immunoglobulin, Hyaluronidase) for Patients with Primary Immunodeficiency Diseases

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Dermatomyositis

Not recruiting

Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin

Postural orthostatic tachycardia syndrome

Not recruiting

Study on the Effectiveness of Human Normal Immunoglobulin for Adults with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Protein

Plasma cell myeloma refractory

Not recruiting

Study of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.